Business Monitor International


Thailand Pharmaceuticals & Healthcare Report

Published 05 February 2014

  • 115 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Thailand Pharmaceuticals & Healthcare Report

BMI View: W e highlight the need for Thailand to address the issue of sustainability. A slowing economy coupled with an ageing population will mean more financial outlays by the government in the future. Heightened political risk is also an ongoing concern as any changes to the political system may potentially change existing policies in the pharmaceutical and healthcare sector.

Headline Expenditure Projections

  • Pharmaceuticals: THB142.5bn (US$4.59bn) in 2013 to THB150.4bn (US$4.84bn) in 2014; +5.5% in local currency terms and +5.3% in US dollar terms.

  • Healthcare: THB498.7bn (US$16.07bn) in 2013 to THB532.2bn (US$17.1bn) in 2014; +7.6% in local currency terms and +7.7% in US dollar terms.

Risk/Reward Rating: In Q2 2014, Thailand is ranked 12th out of the 19 key markets in Asia Pacific. While Thailand's score for its Industry Rewards variable is above the regional average(22.8 versus 20.8), indicating the country's favourable longer-term standing in terms of its pharmaceutical market development, operating risks - including the lacking intellectual property (IP) environment - remain elevated.

Key Trends and Developments

  • In November 2013, the National Health Security Office (NHSO) expanded its coverage for the population:

    • THB32mn (U$993,680) in FY2014 (October 2013 - September 2014) to provide stem cell transplants to patients with white blood cell and lymphoma cancer. The estimated cost of such transplants amounts to THB800,000 (US$24,842) per patient.

    • THB400mn (US$12.4mn) to promote traditional Thai medicines. The NHSO agreed to increase the budget covering the cost of Thai traditional therapies from THB7.20 (US$0.22) to THB8.10 (US$0.25) per person.

  • In the same month, the joint venture (JV) between Thailand's Government Pharmaceutical Organization (GPO) and Sanofi, Government Pharmaceutical Organization-Merieux Biological Products (GPO-MBP), embarked on a THB700mn (US$22.4mn) expansion of its vaccine production facility. This project will take...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
17
Pharmaceutical Market Forecast
17
Table: Thailand Pharmaceutical Sales, Historical Data and Forecasts, 2010-2018
18
Healthcare Market Forecast
19
Table: Thailand Healthcare Expenditure Trends, Historical Data and Forecasts
21
Table: Thailand Government Healthcare Expenditure Trends, Historical Data and Forecasts
21
Table: Thailand Private Healthcare Expenditure Trends, Historical Data and Forecasts
22
Prescription Drug Market Forecast
22
Table: Thailand Prescription Drug Market Indicators, Historical Data and Forecasts
23
Patented Drug Market Forecast
24
Table: Thailand Patented Drug Market Indicators, Historical Data and Forecasts
25
Generic Drug Market Forecast
25
Table: Thailand Generics Drug Market Indicators, Historical Data and Forecasts
26
OTC Medicine Market Forecast
27
Table: Thailand Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
28
Table: OTC Medicine Sales Indicators by Category, 2006-2008
28
Pharmaceutical Trade Forecast
29
Table: Thailand Pharmaceutical Trade Data And Forecasts (US$mn)
31
Table: Thailand Pharmaceutical Trade Data And Forecasts (THBmn)
31
Other Healthcare Data
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
34
Economic Analysis
34
Table: Thailand - Economic Activity
38
Industry Risk Reward Ratings
39
Asia Risk/Reward Ratings
39
Thailand Risk/Reward Ratings
45
Rewards
45
Risks
45
Market Overview
48
Industry Trends And Developments
50
Epidemiology
50
Communicable Diseases
51
Healthcare System
51
Healthcare Insurance
53
Recent Health Insurance Developments
54
Medical Tourism
56
Research And Development (R&D)
56
Biosimilars
57
Clinical Trials
59
Regulatory Development
61
Regulatory Regime
61
Regulatory Development
62
Regional Harmonisation
63
Intellectual Property Regime
63
IP Shortcomings
64
IP Developments
65
Pricing And Reimbursement
66
Table: Price Build-Up Of Medicines In Thailand
67
Competitive Landscape
69
Pharmaceutical Industry
69
Domestic Pharmaceutical Industry
70
Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012
71
Foreign Pharmaceutical Industry
71
Table: PReMA Members
72
Recent Pharmaceutical Industry Developments
72
Pharmaceutical Wholesale
73
Pharmaceutical Retail
75
Company Profile
77
Siam Pharmaceutical
77
Government Pharmaceutical Organisation
79
Biolab
83
Thai Meiji Pharmaceutical Company
85
Berlin Pharmaceutical Industry
87
Pfizer
89
Sanofi
92
GlaxoSmithKline
95
Merck & Co
98
Novartis
101
Demographic Forecast
104
Table: Thailand's Population By Age Group, 1990-2020 ('000)
105
Table: Thailand's Population By Age Group, 1990-2020 (% of total)
106
Table: Thailand's Key Population Ratios, 1990-2020
107
Table: Thailand's Rural And Urban Population, 1990-2020
107
Glossary
108
Methodology
110
Pharmaceutical Expenditure Forecast Model
110
Healthcare Expenditure Forecast Model
110
Notes On Methodology
111
Risk/Reward Ratings Methodology
112
Ratings Overview
113
Table: Pharmaceutical Risk/Reward Ratings Indicators
113
Indicator Weightings
114

The Thailand Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Thailand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Thai pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Thailand to test other views - a key input for successful budgeting and strategic business planning in the Thai pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Thai pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Thailand.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc